SIASUN(SZ:300024) Ge Long Hui A P P·2025-12-30 01:33Group 1 - The company, Jingfeng Medical, has launched an IPO with a global offering of 27.7222 million shares, including 2.7723 million shares for Hong Kong and 24.9499 million shares for international placement, along with an over-allotment option of 4.1583 million shares [1] - The share price is set at HKD 43.24, with expected fundraising of HKD 1.1166 billion if the over-allotment option is not exercised, and up to HKD 1.2892 billion if it is exercised [1] - The company is focused on the surgical robotics sector, having developed multiple models of surgical robots for minimally invasive and non-invasive surgeries since its establishment in 2017 [1] Group 2 - Jingfeng Medical's core products, the Jingfeng® multi-port and single-port surgical robots, commenced commercialization in December 2022 and December 2024, respectively, with 61 global sales agreements signed by June 30, 2025 [2] - The company has completed over 12,000 robotic-assisted clinical surgeries using the multi-port robot and over 2,000 using the single-port robot [2] - Financial data shows revenues of CNY 48.042 million for 2023, CNY 160 million for 2024, and CNY 149 million for the first half of 2025, with a nearly fourfold increase in revenue for the first half of 2025 compared to the same period in 2024 [2] - The gross profit for the first half of 2025 was CNY 93.85 million, representing a year-on-year growth of nearly 390%, making it the industry leader [2] - The company has received support from notable investors aligned with its vision for surgical robotics, including Abu Dhabi Investment Authority, UBS Asset Management, Tencent, and others [2]